Variability of non-clinical behavioral CNS safety assessment: An intercompany comparison

Autor: Himmel, H.M., Delaunois, A., Deurinck, M., Dinklo, T., Eriksson Faelker, T.M., Habermann, C., Heers, C., Hempel, K., Lorenz, H., Rosch, A., Schauerte, H., Teuns, G., Traebert, M., van Amsterdam, C., van der Linde, H.

Publikováno v: In Journal of Pharmacological and Toxicological Methods September-October 2019 99

The effect of a reflective underlay on the global thermal behaviour of pitched roofs

Autor: Roels, S., Deurinck, M.

Publikováno v: In Building and Environment 2011 46(1):134-143

A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.

Autor: Sverdlov O; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States., Curcic J; Novartis Institutes for Biomedical Research, Basel, Switzerland., Hannesdottir K; Novartis Institutes for Biomedical Research, Cambridge, MA, United States., Gou L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States., De Luca V; Novartis Institutes for Biomedical Research, Basel, Switzerland., Ambrosetti F; Novartis Institutes for Biomedical Research, Basel, Switzerland., Zhang B; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC, United States., Praestgaard J; Novartis Institutes for Biomedical Research, Cambridge, MA, United States., Vallejo V; Novartis Institutes for Biomedical Research, Basel, Switzerland., Dolman A; Novartis Institutes for Biomedical Research, Cambridge, MA, United States., Gomez-Mancilla B; Novartis Institutes for Biomedical Research, Basel, Switzerland., Biliouris K; Novartis Institutes for Biomedical Research, Cambridge, MA, United States., Deurinck M; Novartis Institutes for Biomedical Research, Basel, Switzerland., Cormack F; Cambridge Cognition, Cambridge, United Kingdom., Anderson JJ; Neurotrack Technologies, Inc., Redwood City, CA, United States., Bott NT; Department of Medicine, School of Medicine, Stanford University, Stanford, CA, United States., Peremen Z; ElMindA Ltd., Herzliya, Israel., Issachar G; ElMindA Ltd., Herzliya, Israel., Laufer O; ElMindA Ltd., Herzliya, Israel., Joachim D; Sonde Health, Inc., Boston, MA, United States., Jagesar RR; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands., Jongs N; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands., Kas MJ; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands., Zhuparris A; Centre for Human Drug Research, Leiden, Netherlands., Zuiker R; Centre for Human Drug Research, Leiden, Netherlands., Recourt K; Centre for Human Drug Research, Leiden, Netherlands., Zuilhof Z; Centre for Human Drug Research, Leiden, Netherlands., Cha JH; Novartis Institutes for Biomedical Research, Cambridge, MA, United States., Jacobs GE; Centre for Human Drug Research, Leiden, Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, Netherlands.

Publikováno v: Frontiers in psychiatry [Front Psychiatry] 2021 May 06; Vol. 12, pp. 640741. Date of Electronic Publication: 2021 May 06 (Print Publication: 2021).

Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations.

Autor: Guntermann C; Autoimmunity, Transplantation, and Inflammation Disease Area., Piaia A; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland., Hamel ML; CiToxLAB, Evreux, France., Theil D; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland., Rubic-Schneider T; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland., Del Rio-Espinola A; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland., Dong L; Preclinical Safety, Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA., Billich A; Autoimmunity, Transplantation, and Inflammation Disease Area., Kaupmann K; Autoimmunity, Transplantation, and Inflammation Disease Area., Dawson J; Autoimmunity, Transplantation, and Inflammation Disease Area., Hoegenauer K; Global Discovery Chemistry., Orain D; Global Discovery Chemistry., Hintermann S; Global Discovery Chemistry., Stringer R; Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Basel, Switzerland., Patel DD; Autoimmunity, Transplantation, and Inflammation Disease Area., Doelemeyer A; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland., Deurinck M; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland., Schümann J; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Publikováno v: JCI insight [JCI Insight] 2017 Mar 09; Vol. 2 (5), pp. e91127. Date of Electronic Publication: 2017 Mar 09.

Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.

Autor: Barachini, Serena¹ (AUTHOR) gabriele.buda@unipi.it, Buda, Gabriele¹ (AUTHOR), Petrini, Iacopo² (AUTHOR) iacopo.petrini@unipi.it

Publikováno v: Journal of Clinical Medicine. Mar2024, Vol. 13 Issue 6, p1574. 30p.